Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ensemble and Alexion Initiate Collaboration

Published: Friday, July 26, 2013
Last Updated: Friday, July 26, 2013
Bookmark and Share
Goal of discovering small molecule drug candidates for worldwide development and commercialization by Alexion.

Ensemble Therapeutics has announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

The collaboration will deploy Ensemble’s proprietary drug discovery platforms for several undisclosed drug targets identified by Alexion to create highly innovative small molecule therapeutic candidates.

Under the terms of the collaboration, Ensemble will screen its Ensemblin™ collection of more than ten million macrocycles against several disease drug targets specified by Alexion, utilizing Ensemble’s extensive medicinal chemistry capabilities to discover new small molecule clinical candidates.

Alexion will have the exclusive worldwide rights to develop and commercialize candidates arising from the collaboration. Other terms of the agreement were not disclosed; Ensemble will receive an upfront payment and research support, and can earn additional payments upon the achievement of certain development and commercial milestones.

“Ensemble is thrilled to support Alexion’s cutting edge scientific and clinical programs with our ever increasing capability for macrocycle-based drug discovery,” said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics.

“This new collaboration with a leading biopharmaceutical innovator focused on rare diseases speaks to the breadth of utility of Ensemble’s discovery platforms to address clinically important yet challenging drug targets,” Dr. Taylor added.

“Alexion looks forward to a productive collaboration with Ensemble as we seek to broaden the number of pathways toward developing potentially transformative first-in-class drug candidates for patients with selected severe and life-threatening ultra-rare disorders,” said Martin Mackay, PhD, Executive Vice President, Head of Global R&D at Alexion. “This is a promising addition to our development initiatives as we seek to further expand our product portfolio.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!